MarkNtel Advisors recently published a detailed industry analysis of the U.S. Anemia Treatment Market. The report covers growth trends, geographical marketing strategies, challenges, opportunities, and drivers influencing the market.
U.S. Anemia Treatment Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2030
The U.S. Anemia Treatment Market size was valued at around USD 1.07 billion in 2024 and is projected to reach USD 1.98 billion by 2030. Along with this, the market is estimated to grow at a CAGR of around 10.14% during the forecast period, i.e., 2025-30.
What are the major Driver the U.S. Anemia Treatment industry?
Growing Prevalence of Chronic Diseases in the United States – In the U.S., the growing incidence of chronic disease is drastically influencing the dynamics of the Anemia industry. These ailments cause the body to supply insufficient quantities of healthy red blood cells which ends up in anemia. As per the National Institute of Diabetes and Digestive and Kidney Diseases, around 15% of U.S. Adults, which is nearly 37 million, have chronic kidney disorder (CKD). Similarly, chemotherapy is a shape of most cancer treatments that regularly disrupt because of red blood cells, therefore causing anemia. According to the American Cancer Society, almost 1.9 million new cancer cases are diagnosed every year in the U.S., many requiring supportive anemia healing procedures for fatigue management. To meet this demand, erythropoiesis-stimulating agents (ESAs) are notably used to set off crimson blood cell manufacturing amongst patients stricken by CKD or whoever undergoing cancer remedy.
The U.S. healthcare system is witnessing increased use of advanced iron therapies and other anemia management solutions. These developments coupled with the growing healthcare spending and innovation in anemia treatment make the U.S. market a leader in treating anemia caused by chronic disease.
Our Latest Reports Now Include In-Depth Supply Chain Ecosystem Analysis, Enabling Businesses to Navigate Tariff Challenges with Greater Agility Get Sample Report: https://www.marknteladvisors.com/query/request-sample/us-anemia-treatment-market.html
What segments define the U.S. Anemia Treatment market from 2025 to 2030? How do these segments contribute to market dynamics and growth?
- By Disease Type
- Iron Deficiency Anemia-Market Size & Forecast 2020-2030, (USD Million)
- Sickle Cell Anemia-Market Size & Forecast 2020-2030, (USD Million)
- Aplastic Anemia-Market Size & Forecast 2020-2030, (USD Million)
- Vitamin Deficiency Anemia-Market Size & Forecast 2020-2030, (USD Million)
According to report, Based on disease type, vitamin deficiency Anemia, the most common form of Macrocytic Anemia (High MCV), has the largest market share of around 30% in the U.S.
- By Drug
- Bone Marrow Stimulants- Market Size & Forecast 2020-2030, (USD Million)
- Gene Therapy- Market Size & Forecast 2020-2030, (USD Million)
- Corticosteroids- Market Size & Forecast 2020-2030, (USD Million)
- Iron Chelating Agents-Market Size & Forecast 2020-2030, (USD Million)
- Supplements-Market Size & Forecast 2020-2030, (USD Million)
- Iron-Market Size & Forecast 2020-2030, (USD Million)
- Vitamin B12-Market Size & Forecast 2020-2030, (USD Million)
- Folic Acid-Market Size & Forecast 2020-2030, (USD Million)
According to report, Dietary supplements have the most important marketplace proportion around 40%.
Explore the Complete U.S. Anemia Treatment Market Analysis Report – https://www.marknteladvisors.com/research-library/us-anemia-treatment-market.html
Geographical Analysis: U.S. Anemia Treatment Market
- North
- East
- Mid-West
- South
U.S. Anemia Treatment Market Share & Competitive Landscape:
The U.S. Anemia Treatment Market is characterized by intense competition, with several key players driving growth through innovation, market expansion, and strategic investments. The competitive landscape provides valuable insights into the industry’s leading companies, highlighting their strengths, financial performance, and market influence.
Leading Companies in the U.S. Anemia Treatment Market are:
- Pfizer
- Novartis
- Roche
- Amgen
- Bayer
- Teva Pharmaceuticals
- AMAG Pharmaceuticals
- Akebia Therapeutics
- Janssen Pharmaceuticals, Inc.
- Vifor Pharma Management Ltd.
- Abbott
- Sanofi.
U.S. Anemia Treatment Industry Recent Development:
- September 2024: Pfizer Inc. announced that it voluntarily withdrew all lots of OXBRYTA® (voxelotor) for the treatment of sickle cell disease (SCD) in all approved markets. Additionally, Pfizer discontinued all active voxelotor clinical trials and expanded access programs worldwide.
Questions Addressed in this Study
1. What factors are driving the U.S. Anemia Treatment Market growth?
2. How is the U.S. Anemia Treatment Market expected to grow over the next five years?
3. What are the key insights into the current trends in the U.S. Anemia Treatment Market?
4. What is the current size of the U.S. Anemia Treatment Market, and how is it projected to change in the future?
6.What is the future outlook for the U.S. Anemia Treatment Market in terms of technological advancements and market expansion?
For a Customized Analysis Report, Just Drop Your Inquiry Here – https://www.marknteladvisors.com/query/request-customization/us-anemia-treatment-market.html
Why MarkNtel Advisors?
MarkNtel Advisors is a leading research, consulting, & data analytics firm that provides an extensive range of strategic reports on diverse industry verticals. We deliver data to a substantial & varied client base, including multinational corporations, financial institutions, governments, & individuals, among others.
Our specialization in niche industries & emerging geographies allows our clients to formulate their strategies in a much more informed way and entail parameters like Go-to-Market (GTM), product development, feasibility analysis, project scoping, market segmentation, competitive benchmarking, market sizing & forecasting, & trend analysis, among others, for 15 diverse industrial verticals.
More Research Studies Report:
–Biocomposites Market size was valued at around USD 36.9 billion in 2024 and is projected to reach USD 89 billion by 2030 with a CAGR of around 16%.
–Green Solvents Market size was valued at around USD 1.34 billion in 2024 & is projected to reach USD 1.87 billion by 2030 with a CAGR of around 5.7%.
For Media Inquiries, Please Contact:
Email: sales@marknteladvisors.com
Sales Office: 564 Prospect St, B9, New Haven, Connecticut, USA-06511
Corporate Office: Office No.109, H-159, Sector 63, Noida, Uttar Pradesh-201301, India
